[11C]dihydrotetrabenazine Positron Emission Tomography in Manganese-Exposed Workers

Overview

Journal J Occup Environ Med

Specialty Environmental Health

Date 2020 May 31

PMID 32472844

Citations 2

Authors

Susan R Criswell

Susan Searles Nielsen

Mark N Warden

Joel S Perlmutter

Stephen M Moerlein

Lianne Sheppard

Jason Lenox-Krug

Harvey Checkoway

Brad A Racette

Affiliations

Soon will be listed here.

Abstract

Objective: To understand the neurotoxic effects of manganese (Mn) exposure on monoaminergic function, utilizing [C]dihydrotetrabenazine (DTBZ) positron emission tomography (PET) to measure vesicular monoamine transporter 2 (VMAT2).

Methods: Basal ganglia and thalamic DTBZ binding potentials (BPND) were calculated on 56 PETs from 41 Mn-exposed workers. Associations between cumulative Mn exposure, regional BPND, and parkinsonism were examined by mixed linear regression.

Results: Thalamic DTBZ BPND was inversely associated with exposure in workers with less than 3 mg Mn/m-yrs, but subsequently remained stable. Pallidal DTBZ binding increased in workers with less than 2 mg Mn/m-yrs of exposure, but decreased thereafter. Thalamic DTBZ binding was inversely associated with parkinsonism (P = 0.003).

Conclusion: Mn-dose-dependent associations with thalamic and pallidal DTBZ binding indicate direct effects on monoaminergic VMAT2. Thalamic DTBZ binding was also associated with parkinsonism, suggesting potential as an early biomarker of Mn neurotoxicity.

Citing Articles

Update: Protective and risk factors for Parkinson disease.

Grotewold N, Albin R Parkinsonism Relat Disord. 2024; 125:107026.

PMID: 38879999 PMC: 11846500. DOI: 10.1016/j.parkreldis.2024.107026.

Depression and anxiety in a manganese-exposed community.

Racette B, Nelson G, Dlamini W, Hershey T, Prathibha P, Turner J Neurotoxicology. 2021; 85:222-233.

PMID: 34087333 PMC: 8635218. DOI: 10.1016/j.neuro.2021.05.017.

Severity of parkinsonism associated with environmental manganese exposure.

Racette B, Nelson G, Dlamini W, Prathibha P, Turner J, Ushe M Environ Health. 2021; 20(1):27.

PMID: 33722243 PMC: 7962371. DOI: 10.1186/s12940-021-00712-3.

References

Chang C, Hsiao I, Huang S, Lui C, Yen T, Chang W . ¹⁸F-FP-(+)-DTBZ positron emission tomography detection of monoaminergic deficient network in patients with carbon monoxide related parkinsonism. Eur J Neurol. 2015; 22(5):845-52, e59-60. DOI: 10.1111/ene.12672. View

Sun J, Xu J, Cairns N, Perlmutter J, Mach R . Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. PLoS One. 2012; 7(11):e49483. PMC: 3504049. DOI: 10.1371/journal.pone.0049483. View

Hobson A, Sterling D, Emo B, Evanoff B, Sterling C, Good L . Validity and reliability of an occupational exposure questionnaire for parkinsonism in welders. J Occup Environ Hyg. 2009; 6(6):324-31. PMC: 2879629. DOI: 10.1080/15459620902836856. View

Hershey T, Black K, Carl J, McGee-Minnich L, Snyder A, Perlmutter J . Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003; 74(7):844-51. PMC: 1738560. DOI: 10.1136/jnnp.74.7.844. View

Li S, Jiang L, Fu X, Huang S, Huang Y, Li X . Pallidal index as biomarker of manganese brain accumulation and associated with manganese levels in blood: a meta-analysis. PLoS One. 2014; 9(4):e93900. PMC: 3981755. DOI: 10.1371/journal.pone.0093900. View

de la Fuente-Fernandez R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au W . Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol. 2011; 69(5):803-10. DOI: 10.1002/ana.22284. View

Bohnen N, Albin R, Koeppe R, Wernette K, Kilbourn M, Minoshima S . Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006; 26(9):1198-212. DOI: 10.1038/sj.jcbfm.9600276. View

Kim J, Kim J, Kim Y, Shin J, Choi S, Kim S . Dopamine transporter SPECT of a liver cirrhotic with atypical parkinsonism. Ind Health. 2007; 45(3):497-500. DOI: 10.2486/indhealth.45.497. View

Henderson J, Carpenter K, Cartwright H, Halliday G . Degeneration of the centré median-parafascicular complex in Parkinson's disease. Ann Neurol. 2000; 47(3):345-52. View

10.

Parmalee N, Aschner M . Manganese and aging. Neurotoxicology. 2016; 56:262-268. DOI: 10.1016/j.neuro.2016.06.006. View

11.

Yee R, Irwin I, Milonas C, Stout D, Huang S, Satyamurthy N . Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord. 2001; 16(5):838-48. DOI: 10.1002/mds.1168. View

12.

Hobson A, Seixas N, Sterling D, Racette B . Estimation of particulate mass and manganese exposure levels among welders. Ann Occup Hyg. 2010; 55(1):113-25. PMC: 3020674. DOI: 10.1093/annhyg/meq069. View

13.

Criswell S, Searles Nielsen S, Warden M, Perlmutter J, Moerlein S, Flores H . [F]FDOPA positron emission tomography in manganese-exposed workers. Neurotoxicology. 2017; 64:43-49. PMC: 5758438. DOI: 10.1016/j.neuro.2017.07.004. View

14.

HOFFMAN B, Hansson S, Mezey E, Palkovits M . Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol. 1998; 19(3):187-231. DOI: 10.1006/frne.1998.0168. View

15.

Huang C, Liu C, Tsao E, Hsieh C, Weng Y, Hsiao I . Chronic manganism: A long-term follow-up study with a new dopamine terminal biomarker of 18F-FP-(+)-DTBZ (18F-AV-133) brain PET scan. J Neurol Sci. 2015; 353(1-2):102-6. DOI: 10.1016/j.jns.2015.04.018. View

16.

Pavese N, Rivero-Bosch M, Lewis S, Whone A, Brooks D . Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. Neuroimage. 2011; 56(3):1463-8. DOI: 10.1016/j.neuroimage.2011.03.012. View

17.

Wilson J, Levey A, Rajput A, Ang L, Guttman M, Shannak K . Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology. 1996; 47(3):718-26. DOI: 10.1212/wnl.47.3.718. View

18.

Cho S, Christopher L, Koshimori Y, Li C, Lang A, Houle S . Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. Neurobiol Dis. 2018; 124:176-182. DOI: 10.1016/j.nbd.2018.11.022. View

19.

Racette B, Searles Nielsen S, Criswell S, Sheppard L, Seixas N, Warden M . Dose-dependent progression of parkinsonism in manganese-exposed welders. Neurology. 2016; 88(4):344-351. PMC: 5272970. DOI: 10.1212/WNL.0000000000003533. View

20.

Racette B, Criswell S, Lundin J, Hobson A, Seixas N, Kotzbauer P . Increased risk of parkinsonism associated with welding exposure. Neurotoxicology. 2012; 33(5):1356-61. PMC: 3651999. DOI: 10.1016/j.neuro.2012.08.011. View